# NIH Reporter #5R01CA272771-04

The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer

**Recipient:** Roswell Park Cancer Institute, Buffalo, NY

**Award Amount:** $468,436.00
**Ceiling:** $468,436.00

**Awarded:** February 27, 2026

**Identifier:** 5R01CA272771-04

The award supports research on the USP27X enzyme's regulation of Cyclin D1 in HER2 therapy-resistant breast cancer, aiming to develop new therapeutic strategies to overcome drug resistance.

### Description

This project aims to understand USP27X's role in CCND1 regulation and its potential as a therapeutic target in overcoming resistance to HER2-targeting agents in breast cancer patients. USP27X is a deubiquitinating enzyme critical for CCND1 stability, and its inhibition could reduce tumor growth and increase sensitivity to HER2 and CDK4/6 inhibitors.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11295402)